目的 分析溃疡性结肠炎患者采用益生菌治疗的疗效及对肠屏障功能的影响.方法 选择本院2016年9月至2018年3月诊治的160例轻-中度溃疡性结肠炎患者,随机分成研究组(80例)及对照组(80例),对照组使用美沙拉嗪治疗,研究组予以美沙拉嗪与益生菌联合治疗,比较两组疗效.结果 研究组治疗后D-乳酸水平(1.52±0.48)μg/mL、L/M(0.151±0.028)优于对照组(P<0.05);研究组IFN-γ(2.31±0.72)pg/ml、IL-6(9.34±3.05)pg/ml、TNF-α(1.64±0.53)ng/ml,优于对照组(P<0.05);研究组不良反应发生率3.75％,低于对照组(P<0.05).结论 益生菌在溃疡性结肠炎患者中的应用效果确切,可改善肠屏障功能,减轻炎症反应,且不良反应少,安全可靠.%Objective To analyze the efficacy of probiotics in patients with ulcerative colitis and its effect on intestinal barrier function. Methods A total of 160 patients with mild-to-moderate ulcerative colitis who were treated in our hospital from September 2016 to March 2018 were randomly divided into study group (80 cases) and control group (80 cases). The control group was given mesalazine treatment, and the study group was treated with combination of mesalazine and probiotics. Then the efficacy of the two groups were compared after treatment. Results The levels of D-lactate [(1.52±0.48)μg/ml] and L/M [(0.151±0.028)] in the study group after treatment were better than those in the control group (P<0.05); the levels of IFN-γ [(2.31±0.72)pg/ml], IL-6 [(9.34±3.05)pg/ml], TNF-α [(1.64±0.53)ng/ml] in the study group after treatment were better than those in the control group (P<0.05). The incidence of adverse reactions in the study group was 3.75％, which was lower than that in the control group (P<0.05). Conclusion The application of probiotics in patients with ulcerative colitis was effective, which could improve intestinal barrier function and reduce inflammatory reaction, with fewer adverse reactions, safe and reliable.
展开▼
